The Technical Analyst
Select Language :
Radius Health Inc [RDUS]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Radius Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Radius Health Inc is listed at the  Exchange

-0.61% $18.41

America/New_York / 19 apr 2024 @ 16:00


Radius Health Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 517.58 mill
EPS: -1.536
P/E: -11.99
Earnings Date: Aug 09, 2022
SharesOutstanding: 28.11 mill
Avg Daily Volume: 0.230 mill
RATING 2024-04-19
A+
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Buy
DE: Strong Buy
P/E: Buy
Price To Book: Neutral
QUARTER GROWTHS
1/222/223/224/221/232/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -11.99 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.25x
Company: PE -11.99 | industry: PE 47.78
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 17.46 - 19.36

( +/- 5.15%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-04-08 Kelley Erika K. Buy 0
2024-02-20 Minor Glenda J Buy 95 Class A Common Stock
2024-02-20 Sutherlin Michael W Buy 406 Class A Common Stock
2024-02-20 Shoemaker Leslie L Buy 43 Class A Common Stock
2024-02-20 Jahnke David L Buy 515 Class A Common Stock
INSIDER POWER
-78.77
Last 94 transactions
Buy: 7 552 389 | Sell: 18 343 130

Forecast: 16:00 - $18.41

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $18.41
Forecast 2: 16:00 - $18.41
Forecast 3: 16:00 - $18.41
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $18.41 (-0.61% )
Volume 0.218 mill
Avg. Vol. 0.230 mill
% of Avg. Vol 94.84 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Radius Health Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Radius Health Inc

RSI

Intraday RSI14 chart for Radius Health Inc

Last 10 Buy & Sell Signals For RDUS

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:33sell$24.47N/AActive
Profile picture for
            Radius Health Inc

RDUS

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.

Last 10 Buy Signals

Date Signal @
BLURUSDApr 20 - 03:220.402
FLOWUSDApr 20 - 03:23$0.887
CTSIUSDApr 20 - 03:23$0.203
KSMUSDApr 20 - 03:22$31.41
PERPUSDApr 20 - 03:181.064
KP3RUSDApr 20 - 03:1879.28
METISUSDApr 20 - 03:19$63.22
MXUSDApr 20 - 03:17$5.29
IOTAUSDApr 20 - 03:160.229
SSVUSDApr 20 - 03:1738.22

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.